Regorafenib is a multi-kinase inhibitor that targets VEGFRs, PDGFR, RET, RAF kinases, and other signaling molecules (50), suggesting that its impact on neuroblastoma cells may not be solely due to DHODH inhibition. This evidence concerns the gene PDGFRB and neuroblastoma.